A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

PHASE2CompletedINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

February 3, 2022

Primary Completion Date

February 9, 2024

Study Completion Date

June 13, 2024

Conditions
Chickenpox
Interventions
BIOLOGICAL

Investigational varicella vaccine low potency

1 dose of a low-potency investigational varicella vaccine administered subcutaneously.

BIOLOGICAL

Investigational varicella vaccine medium potency

1 dose of a medium-potency investigational varicella vaccine administered subcutaneously.

BIOLOGICAL

Investigational varicella vaccine high potency

1 dose of a high-potency investigational varicella vaccine administered subcutaneously.

BIOLOGICAL

Licensed varicella vaccine Lot 1

1 dose of a licensed varicella vaccine of Lot 1 administered subcutaneously.

BIOLOGICAL

Licensed varicella vaccine Lot 2

1 dose of a licensed varicella vaccine of Lot 2 administered subcutaneously.

BIOLOGICAL

Measles, mumps, and rubella vaccine

1 dose of a measles, mumps, and rubella vaccine administered subcutaneously.

BIOLOGICAL

Hepatitis A vaccine

1 dose of a hepatitis A vaccine administered intramuscularly.

BIOLOGICAL

13-valent pneumococcal conjugate vaccine

1 dose of a 13-valent pneumococcal conjugate vaccine administered intramuscularly.

Trial Locations (51)

333

GSK Investigational Site, Taoyuan District

10002

GSK Investigational Site, Taipei

10468

GSK Investigational Site, The Bronx

10617

GSK Investigational Site, Tallinn

13210

GSK Investigational Site, East Syracuse

19034

GSK Investigational Site, Fort Washington

22902

GSK Investigational Site, Charlottesville

28203

GSK Investigational Site, Charlotte

29812

GSK Investigational Site, Barnwell

30310

GSK Investigational Site, Atlanta

33613

GSK Investigational Site, Tampa

37388

GSK Investigational Site, Tullahoma

39507

GSK Investigational Site, Gulfport

40447

GSK Investigational Site, Taichung

44121

GSK Investigational Site, Cleveland

45406

GSK Investigational Site, Dayton

45414

GSK Investigational Site, Ohio

50106

GSK Investigational Site, Tartu

54449

GSK Investigational Site, Marshfield

63044

GSK Investigational Site, Bridgeton

68134

GSK Investigational Site, Omaha

68198

GSK Investigational Site, Omaha

72022

GSK Investigational Site, Bryant

72202

GSK Investigational Site, Little Rock

72401

GSK Investigational Site, Jonesboro

77087

GSK Investigational Site, Houston

77539

GSK Investigational Site, Dickinson

78218

GSK Investigational Site, San Antonio

78414

GSK Investigational Site, Corpus Christi

78504

GSK Investigational Site, McAllen

78660

GSK Investigational Site, Pflugerville

83404

GSK Investigational Site, Idaho Falls

84041

GSK Investigational Site, Layton

84067

GSK Investigational Site, Roy

84075

GSK Investigational Site, Syracuse

84095

GSK Investigational Site, South Jordan

84604

GSK Investigational Site, Provo

84790

GSK Investigational Site, St. George

89128

GSK Investigational Site, Las Vegas

90057

GSK Investigational Site, Los Angeles

90240

GSK Investigational Site, Downey

90255

GSK Investigational Site, Huntington Park

90706

GSK Investigational Site, Bellflower

91790

GSK Investigational Site, West Covina

92610

GSK Investigational Site, Foothill Ranch

70006-5322

GSK Investigational Site, New Orleans

75230-2571

GSK Investigational Site, Dallas

85-048

GSK Investigational Site, Bydgoszcz

87-100

GSK Investigational Site, Torun

00907

GSK Investigational Site, San Juan

00918

GSK Investigational Site, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT05084508 - A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age | Biotech Hunter | Biotech Hunter